Join CBSET at the MDG Boston Forum: Cutting Edge Advances in Auditory Device Therapies, December 4, 2019, from 4:00 – 7:00 PM at the offices of Foley Hoag LLP, Seaport West, 155 Seaport Boulevard, Boston, MA.
Both CBSET and our partner, CILcare, will be at this event. Celia Belline, Co-founder & CEO of CILcare will be moderating the forum, and Cyrille Sage, R&D Project Manager & Senior Scientist at CILcare will be presenting. This event is championed by Rami Tzafriri and David Parrillo from CBSET.
Hearing loss presents a growing public health problem due to aging, disease, and noise, with the latter disproportionally affecting the young. Overall, ~15% of the global population is affected across all age groups, leading to direct and indirect costs of untreated hearing loss totaling $750 billion.
The diverse needs and challenges of the various auditory diseases have been benefiting from advances in implantable devices, drug development and delivery, and regenerative therapies. Each area has its unique opportunities and challenges and many of the exciting opportunities exist at the intersections of disciplines requiring a broad understanding of the field.
The assembled panel at this form includes a mix of entrepreneurs, researchers from academia and industry, and a practicing physician-scientist and his patients, to discuss the medical and patient needs related to hearing loss and otitis, the research and development challenges and the business opportunities in this fast evolving field.
If you would like to meet up with us there, please contact dparrillo@cbset.com.
Related Services and Publications:
- CBSET GLP Preclinical Services
- GLP Preclinical Services for Auditory Safety
- Localized / Targeted Drug Delivery
Stem Cell and Regenerative Therapies for Hearing Loss
by Michael Naimark, Director of Business Development, CBSET, Inc. and Marie-Pierre Pasdelou, PharmD, founder and the Chief Development Officer, CILcare
World Pharma Today, Volume 3, Issue April, 2018
Auditory Therapy, Ototoxicity, and GLP Compliance: Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve?by Michael Naimark, Director of Business Development, CBSET, Inc. and Marie-Pierre Pasdelou, PharmD, founder and the Chief Development Officer, CILcare
Published in World Pharma Today, November 1, 2017